TLDR
- Q2 adjusted EPS came in at $2.77 vs. $2.66 expected; reported EPS was $2.29
- Revenue rose 5.8% YoY to $23.74 billion, beating estimates of $22.8 billion
- JNJ raised full-year revenue guidance to $93.2B–$93.6B and EPS to $10.80–$10.90
- Pipeline progress includes new drug approvals and positive trial data in oncology and neurology
- Shares rose over 2% in premarket trading; stock is up around 7% YTD
Johnson & Johnson (NYSE: JNJ) reported second-quarter 2025 earnings that beat Wall Street expectations and raised its full-year guidance, sending the stock higher in premarket trading. The company continues to benefit from strong performance in both its MedTech and Innovative Medicine segments, with a growing pipeline of therapies poised to drive momentum through the rest of the year.
Adjusted EPS was $2.77, above the consensus of $2.66, while reported EPS stood at $2.29. Revenue rose 5.8% year over year to $23.74 billion, topping analysts’ estimates of $22.8 billion. Operational sales growth was 4.6%, and adjusted operational growth was 3.0%.
🚨Shares in Focus: Johnson & Johnson $JNJ shares are up 2.35% pre-market to $158.81 after beating Q2 earnings.
💰EPS came in at $2.77, compared to the $2.68 consensus estimate.
📈Revenue reached $23.74 billion, surpassing forecasts, driven by strong demand for cancer drug… pic.twitter.com/147gsoJd9I— ABBO News (@ABBONews) July 16, 2025
Outlook Lifted on Pipeline Strength
Buoyed by strong Q2 performance, Johnson & Johnson raised its 2025 sales outlook to $93.2–$93.6 billion, up from the previous range of $91.0–$91.8 billion. Full-year adjusted EPS is now expected to land between $10.80 and $10.90, compared to prior guidance of $10.50 to $10.70.
CEO Joaquin Duato highlighted the company’s pipeline strength, pointing to significant progress across oncology, neuroscience, dermatology, and surgery. Recent milestones include:
- Approval of IMAAVY for generalized myasthenia gravis
- Priority FDA review for TAR-200 in bladder cancer
- Positive CARVYKTI survival data for multiple myeloma
- Ongoing trials for OTTAVA, a robotic surgery system
Duato noted that these programs position J&J for “elevated growth” in the second half of the year, calling them “game-changing” for patients and shareholders.
Business Environment and Market Reaction
Shares of JNJ rose 2.1% in premarket trading, reaching $158.45, as investors responded positively to the earnings beat and upbeat guidance. The stock is up about 7% year to date, outperforming several large-cap peers in the pharmaceutical space.
Despite facing potential tariff pressures on pharmaceutical imports, which the company estimates could cost $400 million in 2025, Johnson & Johnson reaffirmed its long-term commitment to U.S. manufacturing, with $55 billion in investments planned over four years.
Final Take
Johnson & Johnson’s Q2 results signal resilience and growth across its diversified business lines. With a strong balance sheet, robust R&D pipeline, and expanded full-year outlook, JNJ continues to prove why it’s one of the most stable names in healthcare. Investors appear confident that the second half of 2025 could unlock even more upside, driven by drug approvals and innovation in MedTech.
